|
|||||
|
|
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway |
|
| Authors: | Laura A. Stransky Sean M. Vigeant Bofu Huang Destiny West Thomas Denize Emily Walton Sabina Signoretti William G. Kaelin Jr. |
| Affiliation: | aDepartment of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215;bDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115;cHHMI, Chevy Chase, MD, 20815 |
| Abstract: | |
| Keywords: | ccRCC HIF VHL TP53 belzutifan |